Becton, Dickinson and (BDX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Becton, Dickinson and

NYSE•Healthcare•Medical Instruments & Supplies

$181.38-0.47(<0.01%)After hours

Market Cap

$49.60B

P/E

52.7x

P/S

2.4x

P/B

2.0x

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

How this company scores

AverageMetricSide Score: 59/100

Strongest: Cash & Earnings Quality (23/25); weakest: Growth (8/25).

Profitability9/25

Growth8/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality23/25

Strengths

Cash-backed earningsConsistent free cash flowImproving leverageImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 52.7x5y range 24.5x – 52.7x

Currently above its 20-quarter median.

P/S · 2.4x5y range 1.8x – 3.2x

Currently near its 20-quarter median.

P/B · 2.0x5y range 1.5x – 2.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 19.2% — watch for continued compression, which may signal competitive or cost pressure.

Price & Volume

Market Cap $49.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $20.84B
Q. Revenue: $4.98B
TTM EBITDA: $4.81B
TTM Op. Income: $2.01B
Q. Op. Income: $663.00M
TTM Net Income: $941.00M
Q. Net Income: $377.00M
EPS: $1.37
Shares Out.: $275.18M

$20.84B in TTM revenue declined 2.6% YoY, reaching $4.98B last quarter. TTM EBITDA of $4.81B and TTM operating income of $2.01B show growth is flowing through to the bottom line. TTM net income of $941.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 46.5%
EBITDA Margin: 24.6%
Op. Margin: 13.3%
Net Margin: 7.6%

Op. margin of 13.3% is down 2.7% YoY — costs are rising relative to revenue. Net margin at 7.6% and gross margin of 46.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 17% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 52.7x
P/S Ratio: 2.4x
P/B Ratio: 2.0x

At 52.7x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.4x and P/B of 2.0x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $50.73B
Cash: $708.00M
Long-Term Debt: $13.51B
Book Value: $24.42B
D/E Ratio: 0.6
Debt/EBITDA: 11.0

With $50.73B in assets and $13.51B in long-term debt, D/E is 0.6and book value is $24.42B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $776.00M
TTM Free Cash Flow: $2.73B
FCF Margin: 13.1%
FCF / Net Income: 2.9

TTM FCF of $2.73B on $776.00M in operating cash flow. The FCF / Net Income ratio of 2.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 7% — a weakening trend.